Mach7 Technologies Ltd. · ASX:M7T
Mach7 Technologies — Shareholder Meeting (November 2025)
57 slides from Mach7 Technologies's shareholder meeting presentation, Nov 28, 2025
Slide 1: 2025 Annual General Meeting Chair & CEO Addresses and Presentation
ASX Announcement 28 November 2025 2025 ANNUAL GENERAL MEETING CHAIR & CEO ADDRESSES AND PRESENTATION Mach7 Technologies Limited (“M7T” or “the Company”) (ASX:M7T), a company specialising in innovative medical imaging software solutions, today provides in accordance with ASX Listing Rule 3.13.3, the
Slide 2: Forward-looking statements
ASX Announcement Forward-looking statements This announcement may contain forward-looking statements regarding the Company’s financial position, business strategy and objectives (rather than being based on historical or current facts). Any forward -looking statements are based on the current beliefs
Slide 3: Chair's Address
Mach7 Technologies Ltd Annual General Meeting 28 November 2025 Chair’s Address Before moving to the formal part of the meeting, I would like to provide an overview of the 2025 financial year. I will then hand over to our new CEO and Managing Director Teri Thomas. At Mach7, we are in the business of
Slide 4: Chair's Address (continued)
improvement. Excluding the amortisation of acquired intangibles, Mach7 achieved profitability in FY25 with NPATA of A$0.4M compared to a loss of A$1.2M in FY24. 1 During FY25, we implemented an on-market share buy-back as part of our ongoing capital management strategy. During the second half of FY2
Slide 5: CEO and Managing Director's Address
CEO and Managing Director’s Address This is my first AGM presentation as Mach7’s CEO, and before diving in, I want to share one foundational thing about me. I’ve spent my entire adult life in healthcare, mostly in technology, but also as a registered nurse. I’m driven by impact, and Mach7 offers tha
Slide 6: CEO Address: industry trends
First, in healthcare, especially radiology, workforce shortages are real, and they are not going away. Automation and AI are not “nice to haves” they are survival tools. Second, interoperability and data fluidity are critical. If systems do not connect, clinicians can’t deliver safe care. Disconnect
Slide 7: CEO Address: products and Flamingo
The second component is our Enterprise Diagnostic Viewer, eUnity. eUnity is where clinicians meet the images. It delivers fast, diagnostic-quality, fully browser-based viewing from any device, tightly integrated into EMRs, patient portals, and even AWS Health Imaging. It is FDA-approved, including m
Slide 8: CEO Address: innovation priorities
Speaking of costs, I love products with a clear ROI and Flamingo is designed to drive efficiency, extracting value while discarding waste. And yes, flamingos are memorable, which is why you will see them show up in our booth at RSNA, creating interest, sparking conversations, and facilitating fun an
Slide 9: CEO Address: customer closeness and JET Team
And neither do the rest of my senior team, who adopt key customers so that we ALL can make decisions with the voice of the customer in our heads. I expect Mach7 to be a company that listens, learns, and iterates with customers, not at them. This closeness is a competitive advantage we will build upo
Slide 10: CEO Address: commercial engine
secret sauce, where speed directly drives clinician productivity, customer satisfaction and platform retention. 5. Mach7 delivers enterprise-grade imaging capabilities at a value point competitors cannot match. We maintain a compelling economic advantage to drive market share capture and strong ROI
Slide 11: CEO Address: partners
Todd brings a competitive mindset and deep experience in partner engagement, and he will be leading several enhancements to how we support, enable, and co-sell with our partners: equipped, confident, and excited to bring Mach7 into opportunities. We are also improving the tools and the messaging we
Slide 12: CEO Address: Flight Crew model
Speaking of customers, one of the most exciting cultural shifts, and one of the very first changes under my leadership, has been the creation of our Flight Crew model. These are multidisciplinary teams led by our Advocate for Customer Experience, or ACE. Each Flight Crew provides a single point of a
Slide 13: CEO Address: FY26 guidance and levers
This element is vital for an organisation that needs to move more quickly in order to out -nimble the competition! A culture of building and ownership will drive quality and growth, and underpinning it all, is sales. I do believe and repeat internally, “everybody sells.” A few months ago, I began ev
Slide 14: CEO Address: FY26 revenue outlook
timing of subscription revenue recognition, which typically occurs 12–18 months after signing. To bridge this, we’re counting on revenue coming in from the sales pipeline including capital deals in Asia to match or exceed last year’s performance. The real growth driver is new customers. With revital
Slide 15: CEO Address: closing remarks
Mach7 now has: • A stable recurring revenue base • No debt • A strong balance sheet • Improved customer retention • A clear transformation plan • A differentiated product vision aligned with AI adoption • A much stronger commercial engine • Operating leverage from APAC talent For personal use only •
Slide 16: Mach7 Technologies Limited Annual General Meeting November 2025
For personal use only Mach7 Technologies Limited Annual General Meeting 28 November 2025 Mach7 Technologies | ASX: M7T
Slide 17: Board of directors
Board of directors For personal use only Robert Bazzani Eliot Siegel, MD Non-Executive Chairman Non-Executive Director Teri Thomas Rebecca Thompson CEO and Managing Director Non-Executive Director 2
Slide 18: Agenda
Agenda For personal use only 1 Chairman’s Address 2 CEO and Managing Director’s Address 3 Formal Business Unless otherwise stated, all dollar values are in Australian dollars (AUD) 3
Slide 19: Chairman's Address
For personal use only Chairman’s Address Rob Bazzani
Slide 20: For personal use only
For personal use only Mach7 Technologies delivers advanced image data management and diagnostic viewing solutions to healthcare organisations worldwide.
Slide 21: FY25 in review
FY25 in review Strong foundation in place for driving future growth For personal use only 1 Delivered solid growth in revenue, CARR and ARR. 2 Demonstrated cost discipline across the year and met guidance for OPEX growth to be less than FY25 revenue growth. 32% 3 Delivered significant profit improve
Slide 22: FY25 financial highlights
FY25 financial highlights A$33.8M A$25.3M A$30.2M A$23.5M For personal use only Revenue Recurring Revenue3 CARR4 ARR5 Run Rate +A$4.7M or +16% on PCP1 +A$4.3M or +20% on PCP +A$2.3M or +8% on PCP +A$1.5M or +7% on PCP In line with FY25 75% of total revenue In line with updated Guidance2 FY25 Guidanc
Slide 23: Positioning Mach7 for sustainable long-term profitable growth
Positioning Mach7 for sustainable long- term profitable growth For personal use only New customer- Leverage global Customer base Leadership centric model provides footprint to renewal brings with creation of foundation for optimise fresh skills & customer customer-driven resource perspectives design
Slide 24: CEO and Managing Director's Address
For personal use only CEO and Managing Director’s Address Teri Thomas
Slide 25: For personal use only
Ajuo asn yeuosijad J04
Slide 26: Key industry trends
Key industry trends For personal use only Interoperability Workforce and Cybersecurity Cloud & remote and data automation and resilience workflows integration Security is now Hybrid cloud and Shortages in medical Open APIs and EMR1 essential for edge architecture staff drive adoption of interoperabi
Slide 27: Quantifying growth trends
Quantifying growth trends For personal use only Enterprise Imaging AI in Medical Market Growth Imaging Expansion Enterprise imaging market AI in medical imaging market valued at US$2.1B in 2024 is projected to grow rapidly at 20- expected to reach US$4.1B by 35% CAGR from US$1.3B in 2024. 2030 with
Slide 28: Our current products
Our current products For personal use only Vendor Neutral Archive eUnity Enterprise Diagnostic Viewer ✓ Consolidate ALL images across the enterprise ✓ Zero footprint HTML-5 viewer; 100% fidelity ✓ Allows customers to take control of their data ✓ Virtual aggregation of imaging data across the enterpr
Slide 29: Our vision
For personal use only Our vision Mach7 will be the global leader in imaging data independence, powering AI and tele-imaging. 14
Slide 30: Expanded product suite: Mach7 Flamingo Architecture
Expanded product suite: Mach7 Flamingo Architecture eUnity Enterprise Vendor Neutral Archive Flamingo Architecture For personal use only Diagnostic Viewer ✓ Consolidate ALL images across the enterprise ✓ AI enablement within the software PLUS ✓ Zero footprint HTML-5 viewer; 100% fidelity ✓ Modular a
Slide 31: Flamingo: perfect symbol for our evolution
Flamingo: perfect symbol for our evolution Flight (liberation & reach): Rise above PACS/VNA silos; unify research, AI, and clinical For personal use only workflows enterprise-wide. Community & adaptability: Flamingos thrive in varied environments. So does Mach7, across multi-vendor, multi-region net
Slide 32: Additional product innovation directions
Additional product innovation directions For personal use only Cloud eUnity Additional evolution expansion capabilities Expand beyond AWS to other Evolution of eUnity into a full tele-imaging Embedding telemetry and AI-driven cloud providers, intelligent platform, uniting radiology, advanced optimis
Slide 33: Ideal customer profile
Ideal customer profile • Pain points – Data fragmentation, slow image access, vendor lock-in. For personal use only • Key buying drivers – Data independence, AI readiness, fast diagnostics, lower cost of ownership. • Key decision makers – CIO, CMIO, Head of Imaging / Radiology, VP of IT. • We know A
Slide 34: Innovation and operational synergy: JET team and R&D initiatives
Innovation and operational synergy: JET team and R&D initiatives For personal use only Unified leadership for innovation A new CIO role unites Product and Engineering, enhancing commercial focus and speeding product innovation to market. JET team rapid innovation The Just Execute Together (JET) Team
Slide 35: Asia: from quiet outpost to strategic growth engine
Asia: from quiet outpost to strategic growth engine Profitable scaling of product roadmap as expand capability without proportional OPEX growth. For personal use only 1 Establishing a low-cost innovation hub. Engineering costs 40-75% lower vs US. 49% Capitalising on VNA demand in Asia and the Middle
Slide 36: Differentiators
Differentiators For personal use only End-to-end modular architecture for data independence & sovereignty 1 Vendor Neutral Architecture allows customers full control and unrestricted access to their data, with modular components AI & workflow automation drives advanced orchestration 2 Intelligent ru
Slide 37: Commercial transformation
Commercial transformation Profitable growth through improved sales, marketing and partner management. For personal use only Commercial Excellence • Driving a disciplined, scalable, data-driven revenue engine across all channels. • Aligning product, engineering, finance, sales, 49% 58% and customer t
Slide 38: Mach7 partner approach
Mach7 partner approach Partner Level Intended Benefit Outcomes Strategic Reseller Distribution Consulting For personal use only Benefits focused on generating Customized, co-branded campaigns leads and increasing close Strategic GTM rates through joint messaging Lead capture assets instrumented in P
Slide 39: Our go-to-market strategy
Our go-to-market strategy Owning the intersection between strong VNA and world-class viewer, anchored by a memorable name and symbol. For personal use only Demonstrable high- True enterprise data Vendor freedom “AI-ready” data performance zero-footprint unification (DICOM + delivered with practical
Slide 40: RSNA Scientific Assembly and Annual Meeting
For personal use only • 111th Scientific Assembly & Annual Meeting of RSNA (Chicago) • Largest lead-generation event of the year • Nearly 39,000 registrants in 2024 • Participants from 115 countries • Over 412,000 sq ft of technical exhibits with 700+ exhibitors • 20+ Mach7 attendees across booth an
Slide 41: Transforming customer engagement
Transforming customer engagement Flight Crew - revitalising how Mach7 serves its customers and partners. For personal use only One multi-disciplinary customer designated team Led by Advocate for Customer Experience (ACE) Clear accountability improves support response time Delivers consistent Mach7 e
Slide 42: Operating model and performance culture
Operating model and performance culture Reduces execution risk, accelerates delivery timelines and protects margins. For personal use only Reimagined culture Fostering a culture of collaboration and accountability Anchored in radical transparency, fun and strong • "Rules of engagement" with expectat
Slide 43: Mach7 CLIMBS culture code
Mach7 CLIMBS culture code Culture is the execution engine of our strategy. For personal use only Customer first principle Learn and grow Innovate for impact Minimise complexity and move Build with ownership Sell and grow together 28
Slide 44: FY26 expectations
FY26 expectations Context: Extensive transformation underway: customer engagement overhaul, sales For personal use only reset and new CFO + EVP Sales onboarding. FY26 revenue dynamics o Ongoing subscription transition and prior years of low new-logo volume. o Subscription revenue recognised 12–18 mo
Slide 45: FY26 expectations (continued)
FY26 expectations (continued) Operating efficiency For personal use only Cost reallocation expected to keep operating expenses flat on FY25. o APAC footprint shift (40–75% lower talent cost). o Reduced fixed overhead. o Shifted investments in strategic marketing. Building for beyond FY26 o Flamingo
Slide 46: Outlook
For personal use only Outlook
Slide 47: Outlook
Outlook FY26 is a reset year as Mach7 begins the transformation For personal use only of its operations. Implementation of new strategic direction with revitalised leadership team and clear innovation roadmap. Optimise resource allocation across the group to lower long-term cost base and accelerate
Slide 48: Formal Business
For personal use only Formal Business
Slide 49: Financial and Related Reports
Financial and Related Reports Receipt and consideration of financial statements and annual report For personal use only To receive and consider the financial report of the Company and its controlled entities and the related Directors’ and Auditor’s reports in respect of the financial year ended 30 J
Slide 50: Resolution: Adoption of Remuneration Report
Resolution 1 Adoption of Remuneration Report (non-binding resolution). For personal use only To consider and, if thought fit, pass the following resolution as an ordinary resolution: “That for the purpose of section 250R(2) of the Corporations Act 2001 (Cth) and for all other purposes, the Remunerat
Slide 51: Resolution: Re-election of Dr Eliot Siegel
Resolution 2 Re-election of Dr Eliot Siegel as a Director of the Company. For personal use only To consider and, if thought fit, pass the following resolution as an ordinary resolution: “That, for the purpose of Article 47(b)(i) of the Constitution and for all other purposes, Dr Eliot Siegel, who re
Slide 52: Resolution: Issue of Performance Rights to Teri Thomas
Resolution 3 Issue of Performance Rights to Ms Teri Thomas, CEO & Managing Director For personal use only To consider and, if thought fit, pass the following resolution as an ordinary resolution: “That, for the purpose of ASX Listing Rule 10.14, sections 200B and 200E of the Corporations Act, and fo
Slide 53: Resolution: Spill resolution (conditional)
Resolution 4 Spill resolution (conditional) To consider and, if thought fit, pass the following resolution as an ordinary resolution: For personal use only “That, subject to and conditional on at least 25% of the votes cast on Resolution 1 being cast against the adoption of the Remuneration Report:
Slide 54: Questions
For personal use only Questions
Slide 55: Voting
For personal use only Voting
Slide 56: Meeting Closed
For personal use only Meeting Closed
Slide 57: Disclaimer and forward looking statements
Disclaimer “Forward looking” statements Summary of information: This presentation contains general and background information about Mach7 Risks: An investment in M7T securities is subject to investment and other known and unknown risks, Technologies Limited (“M7T”) activities current as at the date
Mach7 Technologies — Shareholder Meeting (November 2025) on 6ix